Literature DB >> 1679212

Evaluation of the effects of PD 134308 (CI-988), a CCK-B antagonist, on the punished responding of squirrel monkeys.

K R Powell1, J E Barrett.   

Abstract

Lever pressing of squirrel monkeys was maintained by a fixed-interval 3-min schedule of food presentation during which every 30th response also produced a brief electric shock. Lever pressing was suppressed during this stimulus (conflict or punishment) compared to that occurring prior to the introduction of shock or, with some monkeys, during an alternate stimulus in which punishment did not occur. PD 134308 (CI-988), administered i.m. (0.03-3.0 mg/kg), increased punished responding but had no effect on non-punished responding. Peak increases of 150% of control occurred at 3.0 mg/kg. There was no indication of sedation at the highest dose of PD 134308 (10.0 mg/kg). By comparison, chlordiazepoxide (1.0-10 mg/kg, i.m.) produced similar effects, except the magnitude of increases in punished responding reached approximately 200% of control performance levels and the higher doses reduced non-punished response rates. PD 134308 produces anxiolytic-like effects in this animal model of anxiety that would suggest potential clinical efficacy in humans of a novel class of compounds with actions at or modulated by cholecystokinin receptors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1679212     DOI: 10.1016/0143-4179(91)90085-w

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  7 in total

1.  Targeted mutation of CCK2 receptor gene modifies the behavioural effects of diazepam in female mice.

Authors:  Sirli Raud; Kertu Rünkorg; Alar Veraksits; Ain Reimets; Aleksei Nelovkov; Urho Abramov; Toshimitsu Matsui; Michel Bourin; Vallo Volke; Sulev Kõks; Eero Vasar
Journal:  Psychopharmacology (Berl)       Date:  2003-04-23       Impact factor: 4.530

2.  The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients.

Authors:  H J van Megen; H G Westenberg; J A den Boer; B Slaap; F van Es-Radhakishun; A C Pande
Journal:  Psychopharmacology (Berl)       Date:  1997-02       Impact factor: 4.530

3.  Differential profile of the CCKB receptor antagonist CI-988 and diazepam in the four-plate test.

Authors:  D J Dooley; I Klamt
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

4.  Effects of the CCKB antagonist L-365, 260 on benzodiazepine withdrawal-induced hypophagia in rats.

Authors:  A J Goudie; M J Leathley
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

5.  Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy.

Authors:  J Shlik; E Vasar; J Bradwejn
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

6.  Failure of CCK receptor ligands to modify anxiety-related behavioural suppression in an operant conflict paradigm in rats.

Authors:  D Charrier; L Dangoumau; A J Puech; M Hamon; M H Thiébot
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

7.  Lack of effect of CCKB receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs.

Authors:  G R Dawson; N M Rupniak; S D Iversen; R Curnow; S Tye; K J Stanhope; M D Tricklebank
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.